
Arno Therapeutics, Inc. – OTC:ARNI
Arno Therapeutics stock price today
Arno Therapeutics stock price monthly change
Arno Therapeutics stock price quarterly change
Arno Therapeutics stock price yearly change
Arno Therapeutics key metrics
Market Cap | 177.65K |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | 0.15 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.43 |
Revenue | N/A |
EBITDA | -11.05M |
Income | -13.73M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArno Therapeutics stock price history
Arno Therapeutics stock forecast
Arno Therapeutics financial statements
Dec 2015 | 0 | -4.02M | |
---|---|---|---|
Mar 2016 | 0 | -3.72M | |
Jun 2016 | 0 | -2.14M | |
Sep 2016 | 0 | -3.84M |
Dec 2015 | 361240 | 8.98M | 2487.36% |
---|---|---|---|
Mar 2016 | 2924361 | 6.94M | 237.58% |
Jun 2016 | 1098803 | 6.31M | 574.93% |
Sep 2016 | 2355629 | 8.06M | 342.58% |
Dec 2015 | -2.14M | 0 | 2.08M |
---|---|---|---|
Mar 2016 | -2.65M | 0 | 5.27M |
Jun 2016 | -1.67M | 0 | -66.69K |
Sep 2016 | -1.14M | 0 | 2.32M |
Arno Therapeutics alternative data
Aug 2023 | 4 |
---|---|
Sep 2023 | 4 |
Oct 2023 | 4 |
Nov 2023 | 4 |
Dec 2023 | 4 |
Jan 2024 | 4 |
Feb 2024 | 4 |
Mar 2024 | 4 |
Apr 2024 | 4 |
May 2024 | 4 |
Jun 2024 | 4 |
Jul 2024 | 4 |
Arno Therapeutics other data
-
What's the price of Arno Therapeutics stock today?
One share of Arno Therapeutics stock can currently be purchased for approximately $0.
-
When is Arno Therapeutics's next earnings date?
Unfortunately, Arno Therapeutics's (ARNI) next earnings date is currently unknown.
-
Does Arno Therapeutics pay dividends?
No, Arno Therapeutics does not pay dividends.
-
How much money does Arno Therapeutics make?
Arno Therapeutics has a market capitalization of 177.65K.
-
What is Arno Therapeutics's stock symbol?
Arno Therapeutics, Inc. is traded on the OTC under the ticker symbol "ARNI".
-
What is Arno Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Arno Therapeutics?
Shares of Arno Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Arno Therapeutics have?
As Jul 2024, Arno Therapeutics employs 4 workers.
-
When Arno Therapeutics went public?
Arno Therapeutics, Inc. is publicly traded company for more then 17 years since IPO on 11 Jun 2008.
-
What is Arno Therapeutics's official website?
The official website for Arno Therapeutics is arnothera.com.
-
Where are Arno Therapeutics's headquarters?
Arno Therapeutics is headquartered at 200 Route 31 North, Flemington, NJ.
-
How can i contact Arno Therapeutics?
Arno Therapeutics's mailing address is 200 Route 31 North, Flemington, NJ and company can be reached via phone at +86 27037170.
Arno Therapeutics company profile:

Arno Therapeutics, Inc.
arnothera.comOTC
4
Biotechnology
Healthcare
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
Flemington, NJ 08822
:
ISIN: US0425642032
: